Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration.

@article{Parodi2014IntravitrealRF,
  title={Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration.},
  author={Maurizio Battaglia Parodi and Pierluigi Iacono and Carlo La Spina and Lorenzo Iuliano and Giuseppe Lo Giudice and Ugo Introini and Francesco Bandello},
  journal={Retina},
  year={2014},
  volume={34 11},
  pages={2167-70}
}
PURPOSE To investigate the effect of intravitreal ranibizumab on extrafoveal choroidal neovascularization secondary to age-related macular degeneration. METHODS Eighteen eyes affected by extrafoveal choroidal neovascularization secondary to age-related macular degeneration were prospectively enrolled in this study. After an initial intravitreal ranibizumab, all patients were reevaluated monthly over 12 months of follow-up. Further retreatments were performed on a pro re nata basis, depending… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS